Nicholas M Donin1,2, Lorna Kwan3, Andrew T Lenis3, Alexandra Drakaki4,5, Karim Chamie3,5. 1. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. nicholasdonin@gmail.com. 2. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. nicholasdonin@gmail.com. 3. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 4. Department of Medicine, Division of Hematology & Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 5. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Abstract
PURPOSE: Lung cancer is common and lethal, and can occur in survivors of previous cancers. We sought to describe the incidence and mortality attributable to second primary lung cancers (SPLC) among survivors of other cancers, and to identify survivors at highest risk. METHODS: We identified adults diagnosed with a localized malignancy from non-pulmonary cancer sites from surveillance, epidemiology, and end results (SEER) data from 1992 to 2008. We explored factors associated with the incidence and death from SPLC using bivariable and multivariable models. Finally, we compared standardized incidence rates for SPLC in our cohort with the control arm of the National Lung Screening Trial (NLST), a randomized lung cancer screening trial. RESULTS: We identified 1,450,837 survivors of non-pulmonary cancers, of whom 25,472 developed SPLC at a mean (SD) follow-up of 5.7 (3.6) years. Over half (57%) of patients with SPLC died of the disease. Survivors of cancer of the hypopharynx, oropharynx, tonsil, and larynx, experienced SPLC at standardized incidence rates which greatly exceeded that observed in the control arm of the NLST (572/100,000 person-years). Additionally, survivors of bladder and esophageal cancer had rates that approached the NLST control arm rate. Increasing age and being divorced/widowed/separated were independent risk factors for SPLC in most primary cancer types. CONCLUSION: The incidence of SPLC in survivors of certain primary cancers greatly exceeds the rate observed in the control arm of the NLST. Further study could help determine if screening for lung cancer in these cancer survivors could prevent death from lung cancer.
RCT Entities:
PURPOSE:Lung cancer is common and lethal, and can occur in survivors of previous cancers. We sought to describe the incidence and mortality attributable to second primary lung cancers (SPLC) among survivors of other cancers, and to identify survivors at highest risk. METHODS: We identified adults diagnosed with a localized malignancy from non-pulmonary cancer sites from surveillance, epidemiology, and end results (SEER) data from 1992 to 2008. We explored factors associated with the incidence and death from SPLC using bivariable and multivariable models. Finally, we compared standardized incidence rates for SPLC in our cohort with the control arm of the National Lung Screening Trial (NLST), a randomized lung cancer screening trial. RESULTS: We identified 1,450,837 survivors of non-pulmonary cancers, of whom 25,472 developed SPLC at a mean (SD) follow-up of 5.7 (3.6) years. Over half (57%) of patients with SPLC died of the disease. Survivors of cancer of the hypopharynx, oropharynx, tonsil, and larynx, experienced SPLC at standardized incidence rates which greatly exceeded that observed in the control arm of the NLST (572/100,000 person-years). Additionally, survivors of bladder and esophageal cancer had rates that approached the NLST control arm rate. Increasing age and being divorced/widowed/separated were independent risk factors for SPLC in most primary cancer types. CONCLUSION: The incidence of SPLC in survivors of certain primary cancers greatly exceeds the rate observed in the control arm of the NLST. Further study could help determine if screening for lung cancer in these cancer survivors could prevent death from lung cancer.
Authors: Teng Zhang; Chengxiu Zhang; Yan Zhong; Yingli Sun; Haijie Wang; Hai Li; Guang Yang; Quan Zhu; Mei Yuan Journal: Front Oncol Date: 2022-08-11 Impact factor: 5.738
Authors: Yusra F Shao; Seongho Kim; John D Cramer; Dina Farhat; Jeffrey Hotaling; Syed Naweed Raza; George Yoo; Ho-Sheng Lin; Harold Kim; Ammar Sukari; Misako Nagasaka Journal: Head Neck Date: 2022-06-17 Impact factor: 3.821